Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Thymine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.50 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.50 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.95 |
| ▸ | DPYD | Q12882 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HBB | P68871 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thymine SCHEMBL15323914 | 0.97 | ATAD2 (1.00) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL5235 | 0.97 | — | — | |
| Thymine SCHEMBL750450 | 0.97 | ATAD2 (1.00) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL17201833 | 0.97 | ATAD2 (1.00) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL29669526 | 0.97 | — | — | |
| Thymine SCHEMBL2724033 | 0.95 | ATAD2 (0.95) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL31403209 | 0.95 | ATAD2 (0.95) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL8649294 | 0.95 | ATAD2 (0.95) | ATAD2DPYDMAPTGAAALDH1A1 | |
| Thymine SCHEMBL4811815 | 0.95 | — | — | |
| Thymine SCHEMBL5176783 | 0.95 | ATAD2 (0.95) | ATAD2DPYDMAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1364973-B1 | FUNCTIONAL SUBSTANCES DERIVED FROM OLIGOOLEFINS HAVING FUNCTIONAL GROUPS AT THE ENDS | SAN EI KOUGYOU CORP (JP) | 2010-11-17 | — | — | EP | claimed |
| US-7229957-B2 | Functional substances derived from oligoolefins having functional groups at the ends | SAN-EL KOUGYOU CORPORATION (JP) | 2007-06-12 | — | — | US | claimed |
| EP-1790669-A2 | Functional substances derived from oligoolefins having functional groups at the ends | San-Ei Kougyou Corporation (JP) | 2007-05-30 | — | — | EP | claimed |
| US-20060211595-A1 | Functional substances derived from oligoolefins having functional groups at the ends | SAN-EI KOUGYOU CORPORATION | 2006-09-21 | — | — | US | claimed |
| US-20040022757-A1 | Functional substances derived from oligoolefins having functional groups at the ends | SAN-EI KOUGYOU CORPORATION (JP) | 2004-02-05 | — | — | US | claimed |
| EP-1364973-A1 | FUNCTIONAL SUBSTANCES DERIVED FROM OLIGOOLEFINS HAVING FUNCTIONAL GROUPS AT THE ENDS | San-Ei Kougyou Corporation (JP) | 2003-11-26 | — | — | EP | claimed |
| WO-1995011205-A1 | PREPARATIONS PROVIDING A NUTRIENT SOURCE FOR PLANTS AND A PROCESS FOR MAKING SUCH PREPARATIONS | PONTON KFT. (HU) | 1995-04-27 | — | — | WO | claimed |
| US-10272101-B2 | Glucan preparations | BIOTHERA INC. (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3072518-B1 | B-GLUCAN TREATMENT OF UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING | BIOTHERA INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20170304352-A1 | GLUCAN PREPARATIONS | HIBERCELL, INC. | 2017-10-26 | — | — | US | disclosed |
| EP-2461870-B1 | COMPOSITION COMPRISING BETA-GLUCAN AND AN EGF-R ANTIBODY OR AN EGF-R ANTAGONIST FOR USE IN THE TREATMENT OF KRAS-MUTATED TUMORS | BIOTHERA INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9610303-B2 | Glucan preparations | BIOTHERA, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-2032180-B1 | GLUCAN PREPARATIONS | BIOTHERA INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-7229957-B2 | Functional substances derived from oligoolefins having functional groups at the ends | SAN-EL KOUGYOU CORPORATION (JP) | 2007-06-12 | — | — | US | disclosed |
| EP-1790669-A2 | Functional substances derived from oligoolefins having functional groups at the ends | San-Ei Kougyou Corporation (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-20070117738-A1 | Functional substances derived from oligoolefins having functional groups at the ends | SAN-EI KOUGYOU CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-7125834-B2 | Functional substances derived from oligoolefins having functional groups at the ends | SAN-EI KOUGYOU CORPORATION (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060211595-A1 | Functional substances derived from oligoolefins having functional groups at the ends | SAN-EI KOUGYOU CORPORATION | 2006-09-21 | — | — | US | disclosed |
| US-20040022757-A1 | Functional substances derived from oligoolefins having functional groups at the ends | SAN-EI KOUGYOU CORPORATION (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1364973-A1 | FUNCTIONAL SUBSTANCES DERIVED FROM OLIGOOLEFINS HAVING FUNCTIONAL GROUPS AT THE ENDS | San-Ei Kougyou Corporation (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10272101-B2 | Glucan preparations | MANBA, DDOST, GYS2 | GAA 40/4885CYP19A1 3924/4885ATAD2 3725/4885 |
| US-20170304352-A1 | GLUCAN PREPARATIONS | MANBA, DDOST, GYS2 | GAA 40/4885CYP19A1 3924/4885ATAD2 3725/4885 |
| US-20040022757-A1 | Functional substances derived from oligoolefins having functional groups at the ends | PFAS, ELOVL1, FABP4 | GAA 2914/4885CYP19A1 2214/4885ATAD2 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.